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Objectives Korea’s Act on the Registration and Evaluation of Chemicals (K-REACH) was
enacted for the protection of human health and the environment in 2015. Considering
that about 2000 new substances are introduced annually across the globe, the extent of
animal testing requirement could be overwhelming unless regulators and companies
work proactively to institute and enforce global best practices to replace, reduce or refine
animal use. In this review, the way to reduce the animal use for K-REACH is discussed.
Methods Background of the enforcement of the K-REACH and its details was reviewed
along with the papers and regulatory documents regarding the limitation of animal experiments and its alternatives in order to discuss the regulatory adoption of alternative tests.
Results Depending on the tonnage of the chemical used, the data required ranges from
acute and other short-term studies for a single exposure route to testing via multiple exposure routes and costly, longer-term studies such as a full two-generation reproducibility toxicity. The European Registration, Evaluation, Authorization and Restriction of
Chemicals regulation provides for mandatory sharing of vertebrate test data to avoid unnecessary duplication of animal use and test costs, and obligation to revise data requirements and test guidelines “as soon as possible” after relevant, validated replacement,
reduction or refinement (3R) methods become available. Furthermore, the Organization
for Economic Cooperation and Development actively accepts alternative animal tests
and 3R to chemical toxicity tests.
Conclusions Alternative tests which are more ethical and efficient than animal experiments should be widely used to assess the toxicity of chemicals for K-REACH registration. The relevant regulatory agencies will have to make efforts to actively adopt and uptake new alternative tests and 3R to K-REACH.
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Introduction
In modern society, chemicals are indispensable for everyday
human life. Numerous chemicals are used to maintain and improve the quality of life, including cosmetics, toiletries, detergents, air fresheners, agrochemicals such as pesticides and fertil-

izers, disinfectants, sterilizers, preservatives and industrial solvents. Chemicals are also employed in the manufacture of various product-comprising ingredients or parts like coatings/paints,
photo-resistant treatments, batteries, automobiles, packaging
and many more uncountable uses. One recent report estimated
that as many as 80000 to 120000 chemicals are currently in use
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Act on the Registration and Evaluation of
Chemicals: Data Requirements, Test
Guidelines and Skyrocketing Animal Use

worldwide, with an additional 2000 chemicals newly introduced each year [1,2]. In Korea, approximately 44000 chemicals are known to be in use and about 300 new chemicals are
newly marketed annually [3]. Accordingly, exposure to humans
and the environment is unavoidable, which can be accompanied
by adverse effects to human health and/or the environment.
The potential danger of chemical exposure and its devastating
outcomes has been strikingly exemplified by the recent tragic accident surrounding oligo(2-(2-ethoxy)ethoxyethyl guanidine
chloride/polyhexamethyleneguanidine, which were inadvertently used to sterilize humidifiers [4]. These chemicals, which
were originally developed as carpet sterilizers, when used in humidifiers, resulted in high doses via inhalational exposure and
unanticipated lung fibrosis, which cost 701 innocent lives,
mostly newborn babies and nursing mothers [5]. To better protect humans and the environment against exposure to toxic
chemicals, the Act on the Registration and Evaluation of Chemicals (K-REACH), was enacted and has been in force since
2015, mandating the registration of a chemical before its release
onto the market with relevant information on human health and
environmental hazards [6].

K-REACH is the Korean version of the European Registration, Evaluation, Authorization and Restriction of Chemicals
(EU-REACH) regulation. K-REACH originally aimed to manage the risk stemming from chemical exposure by providing relevant information on intrinsic hazards and guidance regarding
safe use, such as by providing proper classification and labeling
[7]. In this respect, it is aligned with the United Nation (UN)
Globally Harmonized System of Classification and Labeling of
Chemicals (GHS) [8]. The UN GHS hazard class system categorizes chemicals according to its level of health hazard as an
axis and toxic outcomes or endpoints as another. Accordingly,
the effects of chemicals on the respective toxic endpoints is
evaluated to obtain safety data so the chemical can be properly
classified. Depending on the volume or tonnage of the chemical
used, the level and range of information required varies, as
shown in Table 1. Notably, K-REACH does not incorporate
many of the animal welfare provisions contained in its European
counterpart regulation, e.g., the Article 1 requirement to pro-

Table 1. Requirement of data for Act on the Registration and Evaluation of Chemicals registration						
Field
Physicochemical
property

Hazard on
human
health

Tonnage [no. of test]a
≥1-10< [15]
State of substance
Water solubility
Melting/freezing point
Boiling point
Vapor pressure
Octanol/water partitioning
coefficient
Density
Particle size analysis
Acute toxicity-oral
(acute toxicity-inhalation)
Ames test (bacterial reverse
mutation assay)
Skin irritation/corrosion
Skin sensitization

Hazard on the Acute toxicity on fish
environment Ready biodegradability
Acute daphnia
immobilization test

≥10-100< [26]

≥100-1000 < [37]

≥1000 [47]

Flammability
Explosiveness
Oxidation

Viscosity
Dissociation constant

Acute toxicity-dermal route or
inhalation
Eye irritation/corrosion
Chromosomal aberration test
Genotoxicity test
Repeated dose toxicity study (28 d)
Screening for reproductive/
developmental toxicity
Fresh water algae growth
inhibition test
Biodegradation as a function of pH

Additional genotoxicity test
(reproductive cell and genotoxicity)

Repeated dose toxicity study (90 d)
Teratogenicity
Two-generation reproductive toxicity
Carcinogenicity

Inherent biodegradability
Identification of degradation products
Chronic toxicity on fish
Chronic toxicity on preferred species
daphnia
Acute toxicity on terrestrial plants
Activated sludge respiration inhibition
Adsorption/desorption

Further information on the
environmental fate and behavior
Chronic toxicity on terrestrial plants
Chronic toxicity testing on terrestrial
invertebrates
Further information on adsorption/
desorption depending on the
results of the study
Long-term toxicity to sediment
organisms
Bio-concentration

a

Test items for lower tonnage are also required.						

Page 2 of 9

http://e-eht.org/

Soojin Ha, et al.

mote alternatives to animal testing, the Article 13 requirement
to generate new data wherever possible by means other than
vertebrate animal tests, the Article 25 requirement to avoid unnecessary testing, and the Annex XI rules for waiving or otherwise adapting standard data requirements [9]. According to the
list of tests required by K-REACH shown in Table 1, for chemical substances manufactured or imported in volumes of 1000
tons or more per year, the data package must include 46 test
items; this entails a huge amount of money and resources. Furthermore, to generate health hazard and ecotoxicology packages
using conventional test guideline methods, the animal use
would be astronomical. In the worst case scenario, the number
of animals required per substance would be nearly 6000, just for
the assessment of human health effects, at a cost of more than
1.5 billion Korean won. The number of animals required and
the costs for each test are listed in Table 2.
Given that about 300 chemicals are newly introduced into Korean market every year, the use of animals would be enormous
without any drastic changes. Statistics published recently by the
Korean Ministry of Agriculture, Food and Rural Affairs (MAFRA) reflects a 36.7% increase in experimental animal use between
2012 and 2015 (2012, 1834000; 2013, 1967000; 2014, 2412000;
2015, 2507000) [10]. This problem is not unique to Korea. Following the enactment of REACH in the EU, the European
Chemicals Agency has estimated that 30000 substances will be
registered, requiring upwards of 3.9 million animals to be used in
tests costing €1.6 billion (US$ 2.3 billion) [11,12]. However,
others have suggested that the European Chemicals Agency’s estimates may represent a substantial underestimation of both chemical registrations and animal use, projecting on the order of 68000
substance registrations and use of 54 million animals, respectively

|
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[13]. Thus, the European public has demanded swift action by
authorities and industry to ensure effective sharing of existing
data, uptake of validated alternatives to animal tests, and other
scientifically supported replacement, reduction or refinement
(3R) best practices.

Limitation and Problems of
Conventional Animal Experiments
Conventional animal experiments have been developed and
used on the premise that the responses of animals in the laboratory to chemicals can provide information to predict those of
humans in the real world. However, this basis is somewhat incorrect with respect to species differences in genetic expression,
absorption, distribution, metabolism and excretion, organ susceptibility, immune responses and resistance or tolerance to xenobiotics. This point has been explicitly criticized by Leist and
Hartung [14], who stated that “the human is not a 70 kg rat.” Indeed, rats, one of the most widely exploited experimental animal
species, have different metabolic capacity and immune responses to humans, which seriously undermines the predictability of
the experimental data [15]. Another important point which diminishes the utility of animal experiments is that extreme conditions are generally employed as the “worst case scenario” in
view of chemical exposure levels (extremely high doses ranging
from 10-fold to 1000-fold higher than human exposure levels)
[16], exposure route (forced eyelid eversion for ocular irritant
administration and closure for persistent exposure, or injection
into sutured oral pouches to simulate oral mucosal exposure),
stress (unrealistically stressful conditions like cold or hot conditions), or disease states (no animal naturally exhibits an asthma-

Table 2. Number of animals required for the assessment of human health effects						
Costa per substance
Acute toxicity for oral
Acute toxicity for dermal or inhalation
Skin irritation and corrosion
Skin sensitization
Eye irritation and corrosion
Repeated dose toxicity (28 d)
Repeated dose toxicity (90 d)
In vivo mutagenicity/genotoxicity
Carcinogenicity
Two generation
Reproductive toxicity
Reproductive toxicity screening
Total

2948571b
3338333b
3186000b
13195000b
3186000b
78637500b
90000000c
9580517b
1000000000c
270000000c
62000000 -70000000c
1540071921

Primary species
24
40
3
45
3
60
120
25-80
500
200

Second species

Primary species (second cohorts)

60
100
500
240

675
5975

GLP, good laboratory practice; CRO, contract research organization.
a
Unit Korean won.
b
Ministry of Environment 2016 (average price of 15 GLP-CROs).						
c
From a single GLP-CRO.					
http://e-eht.org/
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like syndrome that is similar to the disease in humans) [17].
Although these experimental approaches may save time (using
a high dose to curtail the time factor) and cost, they frequently produce unrealistic and inaccurate dose-response data for the prediction of human responses. Exemplifying this, endocrine disrupting chemicals generally exhibit unconventional non-linear,
bell-shaped or U-shaped dose-response patterns that cannot be
properly evaluated in high-dose animal experiments [18]. The
dose-limiting toxicity of drug candidates observed in animal
tests mostly do not appear in human clinical trials and the poor
predictability of animal experiments has been observed across
diverse target tissues [19]. Due to the failure of clinical trials by
the appearance of unscreened toxicity during preclinical trials,
enormous amounts of money and time are wasted [20]. In this
context, the development of more human-relevant and advanced methods is necessary to replace or at least to supplement
traditional animal tests.
In addition to the major scientific drawbacks described above,
animal tests have been criticized for their inherent cruelty, for
being excessively time-intensive and resource-intensive, restrictive in the number of substances or mixtures that can be tested,
and of little value in understanding the mechanistic underpinnings of toxicity in the species of ultimate interest.

New Methods as Replacements for
Conventional Animal Tests
The last century has witnessed unprecedented scientific and
technological advances in biology, represented by human whole
genome sequencing [21], the birth of functional genomics [22],
computational biology, and high-speed robot automation of cellbased (in vitro) screening systems [23]. These innovations are
being incorporated into a wide range of health and molecular/
cellular biological research sectors, providing renewed vigor and
inspiration in these areas. Numerous novel and revolutionary
biochemical and molecular tools have been developed through
this innovation, including high throughput assays, quantitative real
time-polymerase chain reaction, flow cytometry, high content assays, gene transfection, reporter gene assays and tissue engineering. in fact, these new tools have helped to understand how toxicants disrupt the normal physiology of the human body at the
cellular and molecular levels, which has contributed to the birth
of molecular and mechanistic toxicology [24]. The resulting
predictions regarding human safety and the risk of a chemical
are potentially more relevant to people than animal tests. In line
with this, the Toxicology for the 21st Century or “Tox21” strategy has been embarked on with a grand vision “to innovate virtually all routine toxicity testing to be conducted in human cells or
Page 4 of 9

cell lines” [25]. These non-animal based new testing methods
enable safety evaluations of a much larger number of substances,
in a more rapid, efficient and cost-effective way. Most importantly, these methods are likely to be more relevant to toxicity in
humans, as well as capable of identifying the cellular mechanisms of toxicity using fewer or no animals [26,27].

Development of Non-animal Based
Alternatives and Their Adoption by
Regulatory Science
Safety and regulatory science is one of most conservative and
slowest-moving sectors in taking up new and novel methods,
since many countries with diverse cultural and socioeconomic
backgrounds must comply with new regulation through so-called
“international and inter-regional harmonization”. Moreover,
there are various stakeholders with conflicting interests even
within a single country. This is understandable, since important
policies like drinking water standards, sewage control, emission
limits, inclusion on positive or negative lists, and authorizing the
use of chemicals are based upon safety evaluations and risk assessments, which often cost enormous amounts of money to
achieve compliance, with serious risks to public health or the environment in the absence of compliance. Prior to implementation, a newly developed method must be compared regarding its
relevance and reliability to the original gold standard method or
targeted toxicity endpoint in humans in a validation trial, which
can take as long as 10 years from the initial research and development steps [28]. The results of validation studies are then subject to
regulatory adoption processes, involving appraisal by experts
with multi-disciplinary backgrounds, often with the participation
of more than one regulatory body from multiple countries.
International regulatory bodies or collaborative organizations
that can represent a large number of countries, like the Organization for Economic Cooperation and Development (OECD),
the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
Use and the International Organization for Standardization
have participated in these review and appraisal processes to accommodate the opinions of member countries. Of these, the
OECD is the most active in publishing and updating new test
guidelines (TGs), along with integrated approaches to testing
and assessment and other guidance materials, which 35 member
countries can follow as the standardized methods. Many in vitro
or in vivo tests with animal replacement, reduction or refinement
potential have been included as TGs recently, as shown in Table 3
[29], indicating 3R concepts applied to TGs, which are classified
according to toxic endpoints. While non-animal tests have been
http://e-eht.org/
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Table 3. OECD TGs and number of animal reduction by an alternative test methods based on 3R						
Toxic endpoint

OECD TG
No.

In vivo/
in vitro

Title

3R

Year

No. of
animals used

2002
2002
2008

20
12
9

2015
2015
2015
2015
2015
2010
2010

3-4
0
0
0
0
24
24

2010

24

2015
2015
2016
2012
2013
2013
2012

0
0
0
1-3
0
0
0

Acute toxicity

420
423
425

Acute oral toxicity: fixed dose procedure
Acute oral toxicity: acute toxic class method
Acute oral toxicity: up-and-down procedure

In vivo
In vivo
In vivo

Skin irritation and
corrosion

404
430
431
435
439
429
442A

Acute dermal irritation/corrosion
In vitro skin corrosion: transcutaneous electrical resistance test method
In vitro skin corrosion: reconstructed human epidermis test method
In vitro membrane barrier test method for skin corrosion
In vitro skin irritation: reconstructed human epidermis test method
Skin sensitization: local lymph node assay
Skin sensitization: local lymph node assay: DA

In vivo
In vitro
In vitro
In vitro
In vitro
In vivo
In vivo

442B

Skin sensitization: local lymph node assay: BrdU-ELISA

In vivo

442C
442D
442E
405
437
438
460

In vitro
In vitro
In vitro
In vivo
In vitro
In vitro
In vitro
In vitro

Replacement

2015

0

In vitro

Replacement

2015

0

428

In chemico skin sensitization: direct peptide reacitivity assay
In vitro skin sensitization: ARE-Nrf2 luciferase test method
In vitro skin sensitisation: human cell line activation test
Acute eye irritation/corrosion
Bovine corneal opacity and permeability test method
Isolated chicken eye test method
Fluorescein leakage test method for identifying ocular corrosives and
severe irritants
Short time exposure In vitro test method for identifying; i) chemicals
inducing serious eye damage and ii) chemicals not requiring
classification for eye irritation or serious eye damage
Reconstructed human cornea-like epithelium test method for identifying
chemicals not requiring classification and labelling for eye irritation or
serious eye damage
Skin absorption: in vitro method

Refinement
Reduction
Refinement/
reduction
Refinement
Replacement
Replacement
Replacement
Replacement
Reduction
Refinement/
reduction
Refinement/
reduction
Replacement
Replacement
Replacement
Refinement
Replacement
Replacement
Replacement

In vitro

Replacement

2004

0

471
473
474
475
476
478
483

Bacterial reverse mutation test
In vitro mammalian chromosomal aberration test
Mammalian erythrocyte micronucleus test
Mammalian bone marrow chromosomal aberration test
In vitro mammalian cell gene mutation tests using the hprt and xprt genes
Rodent dominant lethal test
Mammalian spermatogonial chromosomal aberration test

In vitro
In vitro
In vivo
In vivo
In vitro
In vivo
In vivo

1997
2014
2014
2014
2015
2015
2015

0
0
23-35
45
0
96-120
45

487
488
489

In vitro mammalian cell micronucleus test
Transgenic rodent somatic and germ cell gene mutation assays
In vivo mammalian alkaline comet assay

In vitro
In vivo
In vivo

2014
2013
2014

0
25
25~35

490
421

In vitro mammalian cell gene mutation tests using the thymidine kinase gene
Reproduction/developmental toxicity screening test

In vitro
In vivo

2015
2015

0
90

422

In vivo

2015

90

443

Combined repeated dose toxicity study with the reproduction/
developmental toxicity screening test
Extended one- generation reproductive toxicity study

2012

140

432
453

In vitro 3T3 NRU phototoxicity test
Combined chronic toxicity/carcinogenicity studies

In vitro
In vivo

Replacement
Replacement
Refinement
Refinement
Replacement
Refinement
Refinement/
reduction
Replacement
Refinement
Refinement/
reduction
Replacement
Refinement/
reduction
Refinement/
reduction
Refinement/
reduction
Replacement
Reduction

2004
2009

0
560

Skin sensitization

Eye irritation and
corrosion

491

492

Dermal/ percutaneous
absorption
Mutagenicity/
genotoxicity

Reproductive toxicity

Photo-induced toxicity
Carcinogenicity

In vivo

OECD, Organization for Economic Cooperation and Development; TG, test guidelines; 3R, replacement, reduction or refinement; BrdU-ELISA, bromodeoxyuridine-enzyme-linked immunosorbent assay; ARE-Nrf2, antioxidant responsive element binded NF-E2-related factor 2; DA, developed by Daicel Chemical
Industries, Ltd; NRU, neutral red uptake.

actively developed and widely used in skin or eye irritation tests,
the alternative tests are not yet established for acute toxicity or rehttp://e-eht.org/
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OECD TGs on toxicity tests were first developed in early 1980s,
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(n)

Valid
Expired

15

3
8

5

1
1 1

2
2

1

1
2

3
1

2 2 2 2

3
1

2 2

Ma
y
Ma 12, 19
y 2 81
Ap 6, 19
Oct r 4, 1983
Feb 23, 1984
2 8
Jul 4, 1986
1
Jul 7, 1997
Ma 27, 19 2
y
9
Jul 22,19 5
Sep 21, 1996
Jan 21, 1997
9
Feb 22, 20 8
0
Apr 08, 20 1
No 24, 2002
v
Aug 23, 2002
0
Oct 17, 20 4
0
1
5
Oct , 20 6
Sep 16, 2007
0 0
Jul 8, 2008
2
Jul 3, 20 9
Oct 28, 2010
0 1
Jul 2, 20 1
Sep 26, 2012
Feb 26, 2013
0 1
Jul 5, 2014
28, 5
201
5

2

1
1 3 5
4
4
2
3
2
1

2

6

Figure 1. Number of revision or updates of Organization for Economic
Cooperation and Development test guideline by Dec 2015.

and have been revised continuously by 3R concepts and with
the progression of science. From the 1980s to the early 2000s,
mainly in vivo methods using animals were adopted as TGs, and
the pace of development or the appearance of new methods was
slow. However, since the late 2000s, the TGs have been annually
revised with 3R concepts, and many new alternative animal tests
have been adopted (Table 3), and many old or obsolete TGs
can now be abandoned. The number of TG revisions by year is
shown in Figure 1 [27].
Human biology-based in vitro methods are typically more relevant and predictive, less time-consuming, can accommodate
larger number of chemicals or mixtures than traditional animal
experiments, and can address the mechanism of toxicity using

Table 4. Category and tools employed for OECD TGs based on non-animal based methodology 						
Category
Ex vivo

In vitro

In chemico

OECD TG No.

Toxi endpoints

437

Eye irritation/corrosion

438

Eye irritation/corrosion

460

Eye irritation/corrosion

430

Skin corrosion

431

Skin corrosion

435

Skin corrosion

439

Skin irritation

442D

Skin sensitization

442E

Skin sensitization

491

Eye irritation/corrosion

492

Eye irritation/corrosion

428
471
473
476

Dermal/percutaneous absorption
Mutagenicity/genotoxicity
Mutagenicity/genotoxicity
Mutagenicity/genotoxicity

487
490

Mutagenicity/genotoxicity
Mutagenicity/genotoxicity

432
442C

Photo-cytotoxicity
Skin sensitization

Title

System and tools employed

Bovine corneal opacity and permeability test
method
Isolated chicken eye test method

Isolated corneas from the eyes of cattle
slaughtered (UV absorbance/Opacimeter)
Eyes of slaughtered chicken
(slit-lamp microscopes)
Fluorescein Leakage test method for identifying Confluent monolayer of Madin-Darby canine
ocular corrosives and severe irritants
kidney (UV absorbance)
In vitro skin corrosion: transcutaneous electrical Rat skin disk (voltohmmeter)
resistance test method
In vitro skin corrosion: reconstructed human
Reconstructed human epidermis
epidermis test method
(3D tissue engineering)
In vitro membrane barrier test method for skin Artificial membrane
corrosion
In vitro skin irritation: reconstructed human
Reconstructed human epidermis
epidermis test method
(3D tissue engineering)
In vitro skin sensitization: ARE-Nrf2 luciferase
Cell line which contains the luciferase gene
under the transcriptional control of a
test method
constitutive promoter fused with an are element
(reporter gene assay)
In vitro skin sensitisation: human cell line
Human monocytic leukaemia cell line THP-1
activation test
Short time exposure in vitro test method for
Statens seruminstitut rabbit cornea cells
identifying i) chemicals inducing serious eye
damage and ii) chemicals not requiring
classification for eye irritation or serious eye
damage
Reconstructed human cornea-like epithelium test Reconstructed human cornea-like epithelium
method for identifying chemicals not requiring (3D tissue engineering)
classification and labelling for eye irritation or
serious eye damage
Skin absorption: in vitro method
Viable or non-viable human (animal) skin
Bacterial reverse mutation test
Salmonella typhimurium, escherichia coli
In vitro mammalian chromosomal aberration test Mammalian somatic cells
In vitro mammalian cell gene mutation tests
Mammalian cells (ex. cho, chl)
using the HPRT and XPRT genes
In vitro mammalian cell micronucleus test
Mammalian cells (ex. blood lymphocytes)
In vitro mammalian cell gene mutation tests
L5178Y tk+/-3.7.2C cells for the mouse
using the thymidine kinase gene
lymphoma assay, TK6 tk+/- cells for the TK6
assay
In vitro 3T3 NRU phototoxicity test
Balb/c 3T3 cells
In chemico skin sensitization: direct peptide
Synthetic peptides (LC/UV)
reactivity assay

OECD, Organization for Economic Cooperation and Development; TG, test guideline; UV, ultraviolet; 3D, three-dimensional; HPRT, hypoxanthine-guanine phosphoribosyl transferase; XPRT, xanthine phosphoribosyl transferase; NRU, neutral red uptake; LC, liquid chromatography.
Page 6 of 9
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the framework of an adverse outcome pathway (AOP). By systemically categorizing the biological events leading to adverse
effects into key events between two points, i.e., a molecular initiating event and an adverse outcome, the AOP describes an adverse outcome following exposure to a chemical by a series of
key events and key event relationships that describe the causal relationships between the key events. AOPs are instrumental for establishing the toxic mechanism of an adverse outcome and the
utilization of safety test data at the in vitro, in vivo and human
levels for risk assessments and regulatory applications. In the
best case scenario, the number of animals saved by employing
multiple in vitro tests along with limited in vivo tests will be in
the thousands, which will significantly contribute to animal ethics without compromising predictive capacity or risking human
health or environmental protection.

Even though some methods give quantitative data, their utility
for potency classification or risk assessment has not been fully
validated [32]. In addition, since the alternatives address mostly
a single key event in the series of events constituting a larger
AOP, they cannot provide the full mechanistic information regarding the final outcome of the initial exposure [33]. In this
case, a combination of multiple in vitro assays can be used as an
integrated approach to testing and assessment (IATA) [34]. Indeed, considerable efforts have been directed toward developing
a standardized IATA scheme.

Pros and Cons of In Vitro Alternatives to
Animal Tests

Although many validated and internationally recognized nonanimal methods and strategies are now available and ready for
immediate use in regulatory frameworks such as K-REACH,
their uptake by Korean authorities continues to be less than optimal. Whereas EU-REACH data requirements and guidance
have been or are being amended to incorporate all available
OECD 3R TGs and related best practices, such is not yet the
case with K-REACH [35,36]. This is in part due to the lack of a
“mandatory 3R” requirement under K-REACH and other legislation for the uptake of new methods. In addition, there is a lack
of inter-ministerial cooperation regarding the uptake of new methods. For example, the Korean Centre for the Validation of Alternative Methods has been established under the Ministry of
Food and Drug Safety (MFDS), but does not currently include
participation from other regulatory or research agencies in the
development, validation or regulatory review of non-animal
based methods [37], indicating the inter-ministerial inefficiency
and passive attitudes towards new and more advanced methods.
Delayed implementation of 3R-based alternatives, due to these
inefficiencies, would lead to the unnecessary sacrifice of laboratory animals, even though they are not better than new alternatives for the protection of human health and the environment.
There are also duplicate experiments for substances that have already been tested and assigned GHS classifications, including
chemicals that are known corrosives, fatal if inhaled or probable
carcinogens. The scientific basis for duplicating well-established
test results and regulatory classifications is incomprehensible, particularly where vertebrate animal testing would be involved, and
most notably where such testing (e.g., of corrosives) would result
in the most extreme pain and suffering for the animals involved.
To ensure that the Korean regulatory framework for chemicals, and the general approach to the validation and adoption of

Ultimately and ideally, all animal experiments, including those
with refined or reduced use of animals, are to be changed into
non-animal based methods. These methods can be largely categorized into in chemico, ex vivo and in vitro methods. Approved
OECD TGs fall into these categories, as shown in Table 4.
Since these methods largely employ test-tube or multi-well
plate formats, the throughput is much higher than traditional
animal experiments. For example, the 3D reconstructed human
cornea-like epithelium (RhCE) method can evaluate the ocular
irritancy of 10 test substances in one run, which takes three days
from the delivery of the model [28]. This test is equivalent to 10
tests using the in vivo Draize rabbit eye irritation test, costing the
lives 30 of rabbits and taking at least 10 days from the delivery of
the rabbits [30]. This test can be harnessed to assess multiple
combinations of test conditions like different mixture ratios, diverse exposure scenarios and the addition of metabolic capacity
using a feasible amount of time and money [27]. Moreover,
through targeting a single molecular event on the AOP framework, the conclusions of alternative methods may be more direct and straightforward, which is critical to address the mechanism of toxicity and extrapolation into human responses. For
example, in the direct peptide reactivity assay, an in chemico skin
sensitization test that addresses the haptenization response of a
substance, positive results indicate that the chemical is reactive
and can form protein adducts [31].
Of course, there are limitations and shortcomings of non-animal methods as well. First, most of the alternatives have not advanced into the level of risk assessment, since they only give a
qualitative “yes” or “no” answer, namely hazard identification.
http://e-eht.org/
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3R best practices, do not fall farther behind those of other developed nations, K-REACH data requirements and TGs must be
immediately and frequently amended on regular basis to incorporate all relevant OECD 3R TGs and related best practices, including mandatory data sharing, chemical grouping and readacross to ensure maximum possible reduction of vertebrate animal use and no duplication of existing test results. One overarching regulatory body shall be formed to include all Korean
ministries with a stake in alternative methods and safety assessment, including the MFDS, the Ministry of Environment (MOE),
and the MAFRA to facilitate inter-ministerial cooperation toward the development of a comprehensive government strategy
and funding framework for the reduction and replacement of
animals used for toxicity testing and life sciences research [38].

Conclusion
The implementation of K-REACH will contribute to the safe
use of chemicals by identifying human health effects and ecotoxicity before their introduction to human society and the environment. However, a huge number of laboratory animals are
required to comply with the current Korean guidelines, which is
sometimes unnecessary and can be replaced with alternative
methods. Therefore, in order for K-REACH to be more practically implemented, 3R concepts and alternative to animal tests
(AATs) should be actively accepted, which has been advanced
in the developed countries. Using AATs for safety assessment is
scientific, highly reliable and predictable and may be more human-relevant without inflicting pain and death in laboratory animals. Moreover, the application of AATs may be more economical and effective than animal tests. The implementation of AATs
is also a concern in other chemical sectors such as the food, cosmetics, drug and agrochemical industries. In this regard, the collaboration of the MOE, the MFDS, and MAFRA in Korea is
critical. Korean regulatory authorities should actively communicate and collaborate to follow global trends in safety assessments
and rapidly developing alternative tests.
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